Evidence map›Paper›PMID 40027135›Full record

ArticleFrontiers in oncology2025

A high-throughput screening platform to identify

Yali Xu, Hricha Mishra, Yutaka Furutani, Kaori Yanaka, Hajime Nishimura, Erina Furuhata, Masataka Takahashi, Luc Gailhouste, Yusuke Suenaga, Yoshitaka Hippo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yali XuLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama, Japan.
Hricha MishraLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama, Japan.
Yutaka FurutaniDepartment of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kaori YanakaDepartment of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hajime NishimuraLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama, Japan.
Erina FuruhataLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama, Japan.
Masataka TakahashiLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama, Japan.
Luc GailhousteLaboratory for Brain Development and Disorders, RIKEN Center for Brain Science, Saitama, Japan.
Yusuke SuenagaLaboratory of Evolutionary Oncology, Chiba Cancer Center Research Institute, Chiba, Japan.
Yoshitaka HippoLaboratory of Evolutionary Oncology, Chiba Cancer Center Research Institute, Chiba, Japan.
Wenkui YuDepartment of Intensive Care Unit, The Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Tomokazu MatsuuraDepartment of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Harukazu SuzukiLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama, Japan.
Xian-Yang QinLaboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences, Kanagawa, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MYCN, an oncogene implicated in hepatocellular carcinoma (HCC), is predominantly expressed in cancer stem-like HCC cells. It drives tumorigenicity, metastasis, and therapeutic resistance. In this study, we hypothesized that the pharmacological inhibition of MYCN could represent a novel therapeutic strategy for HCC. To identify inhibitors of MYCN expression, we developed an unbiased, high-throughput screening platform. With this platform, we identified MI202 as a potent inhibitor of

Indexed as

Acot2DDI core librarygRNA libraryhigh-throughput screeningliver cancerMYCN

Identifiers

PMID40027135
PMCPMC11868045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.